WSSAAI 2024 Northwest Allergy Forum
The NWAF is an annual educational conference hosted on alternate years by the Washington and Oregon Societies of Allergy, Asthma and Immunology. In 2024, the NWAF will be hosting by the WSSAAI. The conference is attended by allergists, Fellows in Training, physicians in related specialties as well as Residents, Medical Students and Nurses. The 2-day program with both local and national speakers will cover disease states such as atopic dermatitis, JAK inhibitors, EGPA, chronic rhinosinusitis, asthma biologics and nasal congestion.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and the Washington State Society of Allergy, Asthma & Immunology (WSSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 8 contact hours.
Commercial Support
No commercial support was received for this activity.
Target Audience
Practicing allergists
Allied health professionals
Learning Objectives
At the conclusion of the conference, participants should be able to:
• Summarize safety data and strategic use of immunomodulators for patients with AD during pregnancy/breastfeeding
• Review practice gaps in clinical care and research in AD
• Appreciate the value of endotyping with biomarkers and multi-omics scaling in the management of severe asthma
• Be familiar with the concepts of advanced of MRI and CT imaging of airways in clinical practice to evaluate severe asthma
• Choose the right biologic for the right patient with severe asthma and switch treatment appropriately
• Appreciate the current international guidelines on the medical treatment of chronic rhinosinusitis.
• Understand the rationale behind surgical procedures for chronic rhinosinusitis with and without nasal polyps.
• Recognize the novel procedural in-office options for treating nasal airway obstruction.
• Recognize signs and symptoms of post-nasal drainage.
• Understand the risks and benefits of the various medical and procedural treatment options for significant post-nasal drainage.
• Discuss new and emerging topical and systemic medications in atopic dermatitis
• Identify patient types that would be ideal candidates for these therapies
• Review the efficacy of JAK inhibitors when compared to other systemic therapies
• Discuss the safety of JAK inhibitors and contextualize this in an atopic dermatitis population
• Apply best practices for risk mitigation and patient adherence
• Identify the most effective medical treatments for CRSsNP, CRSwNP and AFRS.
• Evaluate and select evolving therapeutic strategies
• Review mechanisms, current biologics and effects
• Evaluate current clinical data indicating suggesting possible remittive effects of biologics in asthma
Northwest Allergy Forum | October 5-6, 2024
Grand Hyatt, Seattle, WA | 721 Pine Street | Seattle, WA | (206) 774-6300
Saturday, October 5th
6:30am-7:50am Exhibits | Registration | Coffee Break
NWAF General Session
7:50am-8:00am Welcome & Introduction – Ted Song, DO, WSSAAI; Session Moderator – Leonard Altman, MD, WSSAAI
8:00am-9:00am Complementary and Alternative Treatments for Atopic Dermatitis, Vivian Y. Shi, MD, FAAD
9:00am-10:00am “JAK of all trades, Master of Atopic Dermatitis?”, E. James Song, MD, FAAD
10:00am-10:30am Coffee Break | Exhibits
10:30-11:30am AD Treatment in Special Considerations, Vivian Y. Shi, MD, FAAD
11:30am-12:30pm New and Emerging Topical and Systemic Medications in Atopic Dermatitis, E. James Song, MD, FAAD
12:30pm Adjourn
12:30pm-1:30pm WSSAAI/OSAAI State Society Lunch Meetings (Non-CME)
Sunday, October 6th
7:00am-8:00am Exhibits | Coffee Break
NWAF General Session
7:50am-8:00am Welcome & Introduction, Session Moderator – Lahari Rampur, MD– Executive Director
8:00am-9:00am Comprehensive Medical and Surgical Management of Chronic Rhinosinusitis Greg Davis, MD, MPH
9:00am-10:00am Update on Mechanisms and Management of EGPA , Parameswaran Nair, MD, PhD
10:00am-10:30am Coffee Break | Exhibits
10:30am-11:30am Novel, Non-invasive In-Office Treatments for Nasal Congestion and Eustachian Tube Dysfunction, Greg Davis, MD, MPH
11:30am-12:30pm The Concept of Remission in Severe Asthma, Parameswaran Nair, MD, PhD
12:30pm Adjourn
All relevant financial relationships with ineligible companies have been mitigated.
All relevant financial relationships with ineligible companies have been mitigated.
Greg E. Davis, MD, MPH – Speaker
Advisor: Medtronic, Neurent Medical, Optinose
Consultant: Aerin Medical, Medtronic, SpirAir
Researcher: Neurent Medical, SpirAir
Speaker: Aerin Medical
Parameswaran Nair, MD, PhD – Speaker
Consultant: Arrowhead
Grants: Genentech, Roche
Researcher: AstraZeneca, Sanofi
Speaker: AstraZeneca, GSK, Sanofi
Vivian Y. Shi, MD
Consultant: AbbVie, Almirall, Eli Lilly, Incyte, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB
E. James Song, MD
Advisor: Abbvie, Amgen, Arcutis, BMS, Boehringer-Ingelheim, Dermavant, Incyte, Eli Lilly, Janssen, SUN pharma, LEO, Novartis, Alphynn, Sanofi & Regeneron, Pfizer, APOGEE, Galderma, UCB
Consultant: Abbvie, Amgen, Arcutis, BMS, Boehringer-Ingelheim, Dermavant, Incyte, Eli Lilly, Janssen, SUN pharma, LEO, Novartis, Alphynn, Sanofi & Regeneron, Pfizer, APOGEE, Galderma, UCB
Researcher: Abbvie, Amgen, Arcutis, BMS, Incyte, Janssen, SUN pharma, LEO, Pfizer, APOGEE, DermBiont, Corevitas, TARGET
Speaker: Abbvie, Amgen, Arcutis, BMS, Dermavant, Incyte, Eli Lilly, Janssen, SUN pharma, Sanofi & Regeneron, Pfizer, Galderma, UCB
T. Ted Song , DO – Planner & Moderator
Speaker: AstraZeneca
The following have no relevant financial relationships with ineligible companies to disclose:
Leonard C. Altman, MD – Planner & Moderator
Lahari Rampur, MD – Planner & Moderator
Mark Tucker, MD – Planner
Karol Anderson – Planner
Available Credit
- 8.00 AMA PRA Category 1 Credit™
- 8.00 Attendance
- 8.00 CBRN